Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311764 | 0.85 | HTT (0.45) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL29882303 | 0.84 | ASPH (0.59) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL1720696 | 0.84 | ASPH (0.59) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL1720768 | 0.82 | L3MBTL1 (0.46) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL17509160 | 0.82 | P2RX7 (0.42) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL31726092 | 0.81 | SLC6A9 (0.45) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL19583620 | 0.81 | PSMD14 (0.44) | SLC6A9P2RX7CYP2C19KDM4EALDH1A1 | |
| SCHEMBL9927076 | 0.81 | SLC6A9 (0.40) | SLC6A9P2RX7CYP2C19KDM4EASPH | |
| SCHEMBL16857456 | 0.78 | KDM4E (0.53) | KDM4EHTTALDH1A1L3MBTL1 | |
| SCHEMBL18033657 | 0.76 | HDAC6 (0.48) | KDM4EHTTHSD17B10MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | SLC6A9 4664/4885P2RX7 953/4885CYP2C19 1725/4885 |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | SLC6A9 4630/4885P2RX7 939/4885CYP2C19 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.